EMA Authorised: Altuvoct (Efanesoctocog alfa) — Swedish Orphan Biovitrum AB (publ)

View source ↗

Summary

The EMA authorised Altuvoct (efanesoctocog alfa) for Hemophilia A, with orphan medicine designation.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hemophilia

Drugs mentioned

• Altuvoct (efanesoctocog alfa)

Snippet

Status: Authorised. Therapeutic area: Hemophilia A. MAH: Swedish Orphan Biovitrum AB (publ). Decision date: 12/12/2025. Orphan medicine